SLXN (Silexion Therapeutics) Additional Paid-In Capital : $47.57 Mil(As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Silexion Therapeutics Additional Paid-In Capital?

Silexion Therapeutics's quarterly additional paid-in capital increased from Sep. 2024 ($37.00 Mil) to Dec. 2024 ($39.26 Mil) and increased from Dec. 2024 ($39.26 Mil) to Mar. 2025 ($47.57 Mil).

Silexion Therapeutics's annual additional paid-in capital increased from Dec. 2022 ($11.20 Mil) to Dec. 2023 ($11.34 Mil) and increased from Dec. 2023 ($11.34 Mil) to Dec. 2024 ($39.26 Mil).

Silexion Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Silexion Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silexion Therapeutics Additional Paid-In Capital Chart

Silexion Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

Additional Paid-In Capital

11.20

11.34

39.26

Silexion Therapeutics Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Additional Paid-In Capital	Get a 7-Day Free Trial					11.37	11.40	37.00	39.26	47.57

Silexion Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Silexion Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Silexion Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Silexion Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silexion Therapeutics Corp (NAS:SLXN) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

12 Abba Hillel Road, Ramat-Gan, ISR, 5250606

Website

https://silexion.com

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.